Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis and its Sandoz unit, manufacturers of a generic version of the anesthetic sodium thiopental, have taken necessary steps to stop the drug from reaching the US.
Subscribe to our email newsletter
Sodium thiopental is a sedative legally required for US lethal injections.
In a statement, Novartis and Sandoz have said Sandoz has advised all its subsidiaries with locally approved marketing authorizations for sodium thiopental to stop selling it to distributors or third parties that may be selling it to the US, Reuters.com reported.
Sandoz and Novartis said they support only the authorized use of injectable thiopental for inducing anesthesia, and that Sandoz does not market the drug in the US or ship or sell directly to any third party selling it into the US.
Novartis and Sandoz stated that Sandoz was unaware of and unable to monitor or control, the supply chain beyond its direct customers.
Sandoz was not responsible or involved in third party commercial and marketing activities of the aesthetic, reported the news agency.